NANOG Recombinant Monoclonal Antibodies are genetically engineered to bind specifically to the NANOG protein, a transcription factor essential for maintaining the undifferentiated state of pluripotent stem cells . Unlike conventional monoclonal antibodies (mAbs) derived from hybridoma fusion, recombinant antibodies are synthesized in vitro using plasmid vectors and host cell systems (e.g., HEK293 or Expi293F cells) .
Cloning: Antibody variable region DNA is isolated from immunized animals or antibody libraries .
Expression: DNA is inserted into plasmid vectors and transfected into host cells for antibody production .
Purification: Antibodies are purified via affinity chromatography (e.g., Protein A/G) .
This method eliminates the need for animal immunization and allows for precise engineering of antibody properties (e.g., isotype, epitope targeting) .
Epitope Specificity: Targets diverse regions, including the homeodomain (critical for DNA binding) and N-terminal/C-terminal activation domains .
Species Reactivity: Primarily human; some cross-react with mouse (e.g., eBioMLC-51) .
NANOG Recombinant Monoclonal Antibodies are pivotal in studying stem cell biology, cancer, and regenerative medicine.
Pluripotency Maintenance: NANOG overexpression sustains iPSC self-renewal and blocks differentiation .
Cancer Association: Overexpressed in germ cell tumors, embryonal carcinomas, and breast cancer, enabling its use as a diagnostic marker .
Therapeutic Potential: Used in generating virus-free iPSCs for regenerative therapies .
Recombinant antibodies offer distinct advantages, as summarized below:
Attribute | Recombinant Antibody | Traditional Antibody |
---|---|---|
Consistency | Lot-to-lot uniformity due to genetic standardization | Variable affinity/epitope specificity |
Specificity | Engineered to minimize cross-reactivity | Potential off-target binding |
Animal Use | No immunization required | Requires animal immunization |
Scalability | High-throughput production | Limited by hybridoma cell viability |
Customization | Fc engineering (e.g., Fc-tag removal, bispecific) | Fixed isotype and format |
These features make recombinant antibodies ideal for high-throughput screens and reproducible longitudinal studies .
The NANOG recombinant monoclonal antibody is produced using in vitro expression systems. This involves cloning NANOG antibody DNA sequences from immunoreactive rabbits. The immunogen used is a synthesized peptide derived from the human NANOG protein. The NANOG antibody genes are then inserted into plasmid vectors, which are transfected into host cells to enable antibody expression. Following expression, the NANOG recombinant monoclonal antibody undergoes affinity-chromatography purification. It is rigorously tested for functionality in ELISA and FC applications, demonstrating its reactivity with the human NANOG protein.
NANOG protein plays a crucial role in regulating pluripotency and self-renewal in stem cells, particularly in embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). Its functions are essential for early embryonic development, stem cell maintenance, and cell fate determination.